Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA

Journal of RNAi and Gene Silencing

Volumn 10, Issue 1, 2014, Pages 490-499

  Yingyuad, Peerada ^a   Mével, Mathieu ^a   Prata, Carla ^a   Kontogiorgis, Christos ^a,b   Thanou, Maya ^a,b   Miller, Andrew D ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Elastase; Enzyme; Liposomes; Peptide; Triggerable nanoparticles; Triggered release

Indexed keywords

ELASTASE; ENZYME TRIGGERED PEGYLATED SIRNA NANOPARTICLE; GELATINASE A; LIPOPLEX; LIPOSOME; MACROGOL 2000; NANOCARRIER; PLASMID DNA; PROPIDIUM IODIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; NANOPARTICLE;

AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; PARTICLE SIZE; ZETA POTENTIAL; ENZYME INDUCTION; RNA INTERFERENCE; TUMOR CELL;

EID: 84901396278     PISSN: 17470854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aissaoui A, Chami M, Hussein M and Miller AD. 2011. Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles. J Control Rel, 154, 275-284.
2. Argyros O, Wong SP, Niceta M et al. 2008. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther, 15, 1593-1605.
3. Bloomfield VA. 1991. Condensation of DNA by multivalent cations: considerations on mechanism. Biopolymers, 31, 1471-1481.
4. Buyens K, Demeester J, De Smedt SS and Sanders NN. 2009. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes. Langmuir, 25, 4886-4891.
5. Carmona S, Jorgensen MR, Kolli S et al. 2009. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharmaceutics, 6, 706-717.
6. Cheon SH, Lee KH, Kwon JY, Choi SH, Song MN and Kim DI. 2009. Enhanced delivery of siRNA complexes by sonoporation in transgenic rice cell suspension cultures. J Microbiol Biotechnol, 19, 781-786.
7. Drake CR, Aissaoui A, Argyros O et al. 2010. Bioresponsive small molecule polyamines as non-cytotoxic alternative to polyethylenimine. Mol Pharmaceutics, 7, 2040-2055.
8. Han F and Zhu HG. 2010. Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res, 159, 443-450.
9. Harris TJ, von Maltzahn G, Derfus AM, Ruoslahti E and Bhatia SN. 2006. Proteolytic actuation of nanoparticle self-assembly. Angew Chem Int Ed Engl, 45, 3161-3165.
10. Hatakeyama H, Akita H, Kogure K et al. 2007. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther, 14, 68-77.
11. Hyuga S, Nishikawa Y, Sakata K et al. 1994. Autocrine factor enhancing the secretion of M(r) 95,000 gelatinase (matrix metalloproteinase 9) in serum-free medium conditioned with murine metastatic colon carcinoma cells. Cancer Res, 54, 3611-3616.
12. Kamaly N, Kalber T, Ahmad A et al. 2008. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug Chem, 19, 118-129.
13. Kamaly N, Kalber T, Kenny G, Bell J, Jorgensen M and Miller AD. 2010. A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI. Org Biomol Chem, 8, 201-211.
14. Kamaly N, Kalber T, Thanou M, Bell JD and Miller AD. 2009. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug Chem, 20, 648-655.
15. Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D and Coppolino MG. 2009. VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci, 122, 4089-4098.
16. Keller M, Jorgensen MR, Perouzel E and Miller AD. 2003. Thermodynamic aspects and biological profile of CDAN/DOPE and DC-Chol/DOPE lipoplexes. Biochemistry, 42, 6067-6077.
17. Kenny GD, Kamaly N, Kalber TL et al. 2011. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Rel, 149, 111-116.
18. Kolli S, Wong SP, Harbottle R, Johnston B, Thanou M and Miller AD. 2013. pH-Triggered Nanoparticle Mediated Delivery of siRNA to Liver Cells in Vitro and in Vivo. Bioconjug Chem, 24, 314-332.
19. Kostarelos K and Miller AD. 2005. Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem Soc Rev, 34, 970-994.
20. Lin SW, Lee MT, Ke FC et al. 2000. TGFb1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clinical Exp Metastasis, 18, 493-499.
21. Lu N, Ling Y, Gao Y et al. 2008. Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med, 233, 1013-1020.
22. Mevel M, Kamaly N, Carmona S et al. 2010. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Rel, 143, 222-232.
23. Miller AD. 2008a. Synthetic nucleic acid delivery systems in gene therapy. In Encyclopedia of Life Sciences. J. Wiley & Sons, Chichester, UK.
24. Miller AD. 2008b. Towards safe nanoparticle technologies for nucleic acid therapeutics. Tumori, 94, 234-245.
25. Morgunova E, Tuuttila A, Bergmann U and Tryggvason K. 2002. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci USA, 99, 7414-7419.
26. Pak CC, Ali S, Janoff AS and Meers P. 1998. Triggerable liposomal fusion by enzyme cleavage of a novel peptide-lipid conjugate. Biochim Biophys Acta, 1372, 13-27.
27. Pak CC, Erukulla RK, Ahl PL, Janoff AS and Meers P. 1999. Elastase activated liposomal delivery to nucleated cells. Biochim Biophys Acta, 1419, 111-126.
28. Stellas D, El Hamidieh A and Patsavoudi E. 2010. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol, 11, 51.
29. Terada T, Iwai M, Kawakami S, Yamashita F and Hashida M. 2006. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Rel, 111, 333-342.
30. Wang FQ, So J, Reierstad S and Fishman DA. 2005. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer, 114, 19-31.
31. Waterhouse JE, Harbottle RP, Keller M et al. 2005. Synthesis and Application of Integrin Targeting Lipopeptides in Targeted Gene Delivery. ChemBioChem 6, 1212-1223.
32. Yingyuad P, Mevel M, Prata C et al. 2013. Enzyme-Triggered PEGylated pDNA-Nanoparticles for Controlled Release of pDNA in Tumors. Bioconjug Chem, 24, 343-362.